New hope for Hard-to-Treat leukemia: Three-Drug combo targets relapsed AML
NCT ID NCT07423104
First seen Feb 22, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) in people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment, especially those who have already tried a venetoclax-based regimen. The goal is to see if this new combo can achieve remission. The study plans to enroll 24 adults with relapsed/refractory AML or secondary AML from other blood disorders.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.